Literature DB >> 27132280

Chronic myeloid leukemia: reminiscences and dreams.

Tariq I Mughal1, Jerald P Radich2, Michael W Deininger3, Jane F Apperley4, Timothy P Hughes5, Christine J Harrison6, Carlo Gambacorti-Passerini7, Giuseppe Saglio8, Jorge Cortes9, George Q Daley10.   

Abstract

With the deaths of Janet Rowley and John Goldman in December 2013, the world lost two pioneers in the field of chronic myeloid leukemia. In 1973, Janet Rowley, unraveled the cytogenetic anatomy of the Philadelphia chromosome, which subsequently led to the identification of the BCR-ABL1 fusion gene and its principal pathogenetic role in the development of chronic myeloid leukemia. This work was also of major importance to support the idea that cytogenetic changes were drivers of leukemogenesis. John Goldman originally made seminal contributions to the use of autologous and allogeneic stem cell transplantation from the late 1970s onwards. Then, in collaboration with Brian Druker, he led efforts to develop ABL1 tyrosine kinase inhibitors for the treatment of patients with chronic myeloid leukemia in the late 1990s. He also led the global efforts to develop and harmonize methodology for molecular monitoring, and was an indefatigable organizer of international conferences. These conferences brought together clinicians and scientists, and accelerated the adoption of new therapies. The abundance of praise, tributes and testimonies expressed by many serve to illustrate the indelible impressions these two passionate and affable scholars made on so many people's lives. This tribute provides an outline of the remarkable story of chronic myeloid leukemia, and in writing it, it is clear that the historical triumph of biomedical science over this leukemia cannot be considered without appreciating the work of both Janet Rowley and John Goldman. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27132280      PMCID: PMC5004358          DOI: 10.3324/haematol.2015.139337

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  184 in total

1.  Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.

Authors:  Neil P Shah; François Guilhot; Jorge E Cortes; Charles A Schiffer; Philipp le Coutre; Tim H Brümmendorf; Hagop M Kantarjian; Andreas Hochhaus; Philippe Rousselot; Hesham Mohamed; Diane Healey; Michael Cunningham; Giuseppe Saglio
Journal:  Blood       Date:  2014-02-25       Impact factor: 22.113

2.  The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf.

Authors:  M S Neshat; A B Raitano; H G Wang; J C Reed; C L Sawyers
Journal:  Mol Cell Biol       Date:  2000-02       Impact factor: 4.272

3.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.

Authors:  Moshe Talpaz; Neil P Shah; Hagop Kantarjian; Nicholas Donato; John Nicoll; Ron Paquette; Jorge Cortes; Susan O'Brien; Claude Nicaise; Eric Bleickardt; M Anne Blackwood-Chirchir; Vishwanath Iyer; Tai-Tsang Chen; Fei Huang; Arthur P Decillis; Charles L Sawyers
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

4.  Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Authors:  François-Xavier Mahon; Delphine Réa; Joëlle Guilhot; François Guilhot; Françoise Huguet; Franck Nicolini; Laurence Legros; Aude Charbonnier; Agnès Guerci; Bruno Varet; Gabriel Etienne; Josy Reiffers; Philippe Rousselot
Journal:  Lancet Oncol       Date:  2010-10-19       Impact factor: 41.316

5.  Molecular studies in patients with chronic myeloid leukaemia in remission 5 years after allogeneic stem cell transplant define the risk of subsequent relapse.

Authors:  T I Mughal; A Yong; R M Szydlo; F Dazzi; E Olavarria; F van Rhee; J Kaeda; N C Cross; C Craddock; E Kanfer; J Apperley; J M Goldman
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

Review 6.  Standardized definitions of molecular response in chronic myeloid leukemia.

Authors:  N C P Cross; H E White; M C Müller; G Saglio; A Hochhaus
Journal:  Leukemia       Date:  2012-04-16       Impact factor: 11.528

Review 7.  Chronic myeloid leukaemia.

Authors:  Jane F Apperley
Journal:  Lancet       Date:  2014-12-05       Impact factor: 79.321

Review 8.  Allogeneic transplantation for CML in the TKI era: striking the right balance.

Authors:  Andrew J Innes; Dragana Milojkovic; Jane F Apperley
Journal:  Nat Rev Clin Oncol       Date:  2015-11-17       Impact factor: 66.675

Review 9.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Authors:  Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

10.  Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.

Authors:  F J Giles; P D le Coutre; J Pinilla-Ibarz; R A Larson; N Gattermann; O G Ottmann; A Hochhaus; J P Radich; G Saglio; T P Hughes; G Martinelli; D-W Kim; S Novick; K Gillis; X Fan; J Cortes; M Baccarani; H M Kantarjian
Journal:  Leukemia       Date:  2012-07-05       Impact factor: 11.528

View more
  28 in total

Review 1.  Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Omar Abdel-Wahab; Raajit Rampal; Ruben Mesa; Steffen Koschmieder; Ross Levine; Rüdiger Hehlmann; Giuseppe Saglio; Tiziano Barbui; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2016-05-31

Review 2.  Diagnostic molecular techniques in haematology: recent advances.

Authors:  Aikaterini Koutsi; Elisavet-Christina Vervesou
Journal:  Ann Transl Med       Date:  2018-06

3.  Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection.

Authors:  Lorena Vigón; Sara Rodríguez-Mora; Alejandro Luna; Virginia Sandonís; Elena Mateos; Guiomar Bautista; Juan Luis Steegmann; Nuria Climent; Montserrat Plana; Pilar Pérez-Romero; Fernando de Ory; José Alcamí; Valentín García-Gutierrez; Vicente Planelles; María Rosa López-Huertas; Mayte Coiras
Journal:  Biochem Pharmacol       Date:  2020-08-20       Impact factor: 5.858

Review 4.  Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Jason Gotlib; Ruben Mesa; Steffen Koschmieder; H Jean Khoury; Jorge E Cortes; Tiziano Barbui; Rüdiger Hehlmann; Michael Mauro; Susanne Saussele; Jerald P Radich; Richard A Van Etten; Giuseppe Saglio; Srdnan Verstovek; Robert Peter Gale; Omar Abdel-Wahab
Journal:  Leuk Res       Date:  2018-02-14       Impact factor: 3.156

5.  Bardoxolone methyl (CDDO-Me or RTA402) induces cell cycle arrest, apoptosis and autophagy via PI3K/Akt/mTOR and p38 MAPK/Erk1/2 signaling pathways in K562 cells.

Authors:  Xin-Yu Wang; Xue-Hong Zhang; Li Peng; Zheng Liu; Yin-Xue Yang; Zhi-Xu He; Hong-Wan Dang; Shu-Feng Zhou
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

Review 6.  Recurrent Fusion of the GRB2 Associated Binding Protein 1 (GAB1) Gene With ABL Proto-oncogene 1 (ABL1) in Benign Pediatric Soft Tissue Tumors.

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Kristin Andersen; Svetlana Tafjord; Marius Lund-Iversen; Ingvild Lobmaier; Francesca Micci; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

7.  [Effect of MDR1 and CYP3A5 gene polymorphisms on outcomes of patients receiving imatinib treatment for chronic myeloid leukemia].

Authors:  Ying He; Xiumei Zao; Xuehua Wei
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-01-30

Review 8.  Biogenesis, cellular effects, and biomarker value of circHIPK3.

Authors:  Yihan Fu; Hong Sun
Journal:  Cancer Cell Int       Date:  2021-05-11       Impact factor: 5.722

9.  Interrogating the molecular genetics of chronic myeloproliferative malignancies for personalized management in 2021.

Authors:  Tariq I Mughal; Bethan Psaila; Daniel J DeAngelo; Giuseppe Saglio; Richard A Van Etten; Jerald P Radich
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

10.  Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1T315I and BCR-ABL1T315I-E255K.

Authors:  Afsar Ali Mian; Isabella Haberbosch; Hazem Khamaisie; Abed Agbarya; Larissa Pietsch; Elizabeh Eshel; Dally Najib; Claudia Chiriches; Oliver Gerhard Ottmann; Oliver Hantschel; Ricardo M Biondi; Martin Ruthardt; Jamal Mahajna
Journal:  Ann Hematol       Date:  2021-06-10       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.